Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı
Yıl: 2017 Cilt: 23 Sayı: 2 Sayfa Aralığı: 67 - 73 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı
Öz: Amaç: Daha önce hepatitis B virüs (HBV) enfeksiyonu geçirdiğine dair serolojik kanıtı olan tüm hastalar; immunsupresif tedavi alacak olmaları halinde reaktivasyon riski ile karşı karşıyadırlar. Çalışmamızda; kemik iliği transplantasyonu yapılan hastalarda, HBV infeksiyon/reaktivasyon sıklığı ve reaktivasyona sebep olan olası etmenleri belirlemek amaçlandı.Yöntemler: Çalışmaya Nisan 2011 ve Aralık 2016 tarihleri arasında allojenik ve otolog periferik kök hücre transplantasyonu (PKHT) yapılan 442 hasta alındı. Hepatit B virüs serolojilerine, aldıkları kemoterapi rejimlerine ve antiviral tedavilere retrospektif olarak bakıldı. Bulgular: HBsAg pozitif hasta sayısı 36 (%8,1), HBsAg negatif/Anti-HBc pozitif hasta sayısı 74 (%16,7) olup, hastaların tamamına antiviral tedavi verildi. Medyan 21 aylık izlemde hiç reaktivasyon saptanmadı. Sonuç: İmmunsupresif tedavi alacak tüm hastalar, HBV açısından taranmalı, profilaktik tedavi açısından değerlendirilmelidir. Böylece HBV reaktivasyon riski en aza indirilerek, her zaman hastalara preventif yaklaşım içinde bulunulmalıdır.
Anahtar Kelime: Konular:
The frequency of hepatitis B virus reactivation in patients with bone marrow transplantation
Öz: Objective: All patients with serologic evidence of a previous hepatitis B virus ( HBV )infection have the risk of reactivation. The present study aimed to determine the prevalence of HBV infection/reactivation and to identify possible factors causing reactivation in patients who underwent bone marrow transplantation.Methods: In total, 442 patients who underwent allogeneic and autologous peripheral stem cell transplantation between April 2011 and December 2016 were included. Hepatitis B virus serologies, chemotherapy regimens received, and antiviral treatments were retrospectively evaluated. Results: The number of HBsAg-positive patients was 36 (8.1%) and that of HBsAg-negative/anti-HBc-positive patients was 74 (16.7%); antiviral treatment was given to all patients. There was no HBV reactivation at the median follow-up of 21 months. Conclusion: All patients receiving immunosuppressive therapy should be screened for HBV infection and evaluated for the prophylactic treatment of HBV. Thus, the risk of HBV reactivation is minimized, and a preventive approach should always be considered for patients.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015.
- 2. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61: 703-11. [CrossRef]
- 3. Tosun S. Viral hepatitlerin ülkemizdeki değişen epidemiyolojisi. Ankem Derg 2013; 27: 128-34.
- 4. Tosun S. Türkiye'de viral hepatit B epidemiyolojisi: yayınların meta analizi. In: Tabak F, Tosun S, editors. Viral Hepatit 2013. Ankara: Viral Hepatitle Savaşım Derneği, 2013: 27-80.
- 5. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-44. [CrossRef]
- 6. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28. [CrossRef]
- 7. Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA 2015; 313: 1617-8. [CrossRef]
- 8. Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164: 30-40. [CrossRef]
- 9. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49(5 Suppl): S156-65. [CrossRef]
- 10. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8. [CrossRef]
- 11. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85. [CrossRef]
- 12. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61. [CrossRef]
- 13. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20.
- 14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2. [CrossRef]
- 15. Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol 2010; 17: 32-8. [CrossRef]
- 16. Day FL, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 2011; 7: 141-7. [CrossRef]
- 17. Alvarez-Suarez B, de-la-Revilla-Negro J, Ruiz-Antorán B, Calleja-Panero JL. Hepatitis B reactivation and current clinical impact. Rev Esp Enferm Dig 2010; 102: 542-52. [CrossRef]
- 18. Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving trans arterial chemo-lipiodolization. Hepatology 2006; 43: 233-40. [CrossRef]
- 19. Mozessohn L, Chan KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat 2015; 22: 842-9. [CrossRef]
- 20. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11. [CrossRef]
- 21. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215-9. [CrossRef]
- 22. Bréchot C, Degos F, Lugassy C, Thiers V, Zafrani S, Franco D, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985; 312: 270-76. [CrossRef]
- 23. Chemin I, Jeantet D, Kay A, Trépo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease. Antiviral Res 2001; 52: 117-23. [CrossRef]
- 24. Locasciulli A, Bruno B, Alessandrino EP, Meloni G, Arcese W, Ban¬dini G, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003; 31: 295-300. [CrossRef]
- 25. Senecal D, Pichon E, Dubois F, Delain M, Linassier C, Colombat P. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Trans¬plant 1999; 24: 1243-4. [CrossRef]
- 26. Dhédin N, Douvin C, Kuentz M, Saint Marc MF, Reman O, Rieux C, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and Anti-HBc. Transplantation 1998; 66: 616-9. [CrossRef]
- 27. WangY, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol 2013; 19: 923-30. [CrossRef]
- 28. Mikulska M, Nicolini L, Signori A, Rivoli G, Del Bono V, Raiola AM, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect 2014; 20: O694-701. [CrossRef]
- 29. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86. [CrossRef]
- 30. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42. [CrossRef]
- 31. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712. [CrossRef]
| APA | Balkan A, KIRIK M, GUNDES I, HAYDAROĞLU ŞAHİN H, BÜDEYRİ S, BALKAN Y, Gulsen M, PEHLİVAN M (2017). Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. , 67 - 73. |
| Chicago | Balkan Ayhan,KIRIK Melya Pelin,GUNDES ILKNUR,HAYDAROĞLU ŞAHİN HANDAN,BÜDEYRİ Selin,BALKAN YASEMIN,Gulsen Murat Taner,PEHLİVAN MUSTAFA Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. (2017): 67 - 73. |
| MLA | Balkan Ayhan,KIRIK Melya Pelin,GUNDES ILKNUR,HAYDAROĞLU ŞAHİN HANDAN,BÜDEYRİ Selin,BALKAN YASEMIN,Gulsen Murat Taner,PEHLİVAN MUSTAFA Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. , 2017, ss.67 - 73. |
| AMA | Balkan A,KIRIK M,GUNDES I,HAYDAROĞLU ŞAHİN H,BÜDEYRİ S,BALKAN Y,Gulsen M,PEHLİVAN M Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. . 2017; 67 - 73. |
| Vancouver | Balkan A,KIRIK M,GUNDES I,HAYDAROĞLU ŞAHİN H,BÜDEYRİ S,BALKAN Y,Gulsen M,PEHLİVAN M Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. . 2017; 67 - 73. |
| IEEE | Balkan A,KIRIK M,GUNDES I,HAYDAROĞLU ŞAHİN H,BÜDEYRİ S,BALKAN Y,Gulsen M,PEHLİVAN M "Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı." , ss.67 - 73, 2017. |
| ISNAD | Balkan, Ayhan vd. "Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı". (2017), 67-73. |
| APA | Balkan A, KIRIK M, GUNDES I, HAYDAROĞLU ŞAHİN H, BÜDEYRİ S, BALKAN Y, Gulsen M, PEHLİVAN M (2017). Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. European Journal of Therapeutics, 23(2), 67 - 73. |
| Chicago | Balkan Ayhan,KIRIK Melya Pelin,GUNDES ILKNUR,HAYDAROĞLU ŞAHİN HANDAN,BÜDEYRİ Selin,BALKAN YASEMIN,Gulsen Murat Taner,PEHLİVAN MUSTAFA Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. European Journal of Therapeutics 23, no.2 (2017): 67 - 73. |
| MLA | Balkan Ayhan,KIRIK Melya Pelin,GUNDES ILKNUR,HAYDAROĞLU ŞAHİN HANDAN,BÜDEYRİ Selin,BALKAN YASEMIN,Gulsen Murat Taner,PEHLİVAN MUSTAFA Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. European Journal of Therapeutics, vol.23, no.2, 2017, ss.67 - 73. |
| AMA | Balkan A,KIRIK M,GUNDES I,HAYDAROĞLU ŞAHİN H,BÜDEYRİ S,BALKAN Y,Gulsen M,PEHLİVAN M Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. European Journal of Therapeutics. 2017; 23(2): 67 - 73. |
| Vancouver | Balkan A,KIRIK M,GUNDES I,HAYDAROĞLU ŞAHİN H,BÜDEYRİ S,BALKAN Y,Gulsen M,PEHLİVAN M Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı. European Journal of Therapeutics. 2017; 23(2): 67 - 73. |
| IEEE | Balkan A,KIRIK M,GUNDES I,HAYDAROĞLU ŞAHİN H,BÜDEYRİ S,BALKAN Y,Gulsen M,PEHLİVAN M "Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı." European Journal of Therapeutics, 23, ss.67 - 73, 2017. |
| ISNAD | Balkan, Ayhan vd. "Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı". European Journal of Therapeutics 23/2 (2017), 67-73. |
